Chan-Hee Park

Dr. Park is currently CTO of JW group and CEO of JW Creagene (An affiliate of JW Shinyak). He joined JW Pharmaceutical in 1996 and served as the Chief of Discovery Research Center of C&C Research Laboratoris (Affiliate of JW Pharmaceutical) and Chief of Drug Discoevry Center of JW Pharmaceutical Corp. And currently he also responsible for JW Research Strategy Office of JW Holdings. He also serves as a board of appraisal of KDDF (Korea Drug Development Fund), a member of R&D Policy Board of KPBMA (Korea Pharmaceutical and Bio-pharma Manufacturers Association) as well as a member of TBC (Technology Business Committe) of KDRA (Korea Drug Research Association) in Korea. now also the vice-board president of Korea Pharmaceutical Manufacturers Association (KPMA). He graduated from the Dept. of Chemistry of Sung Kyun Kwan University and received his PhD. degree from Seoul National University.